Cargando…

Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma

Cholestasis, which is impaired bile flow from the liver into the intestine, can be caused by cholangitis and/or bile duct obstruction. Cholangitis can arise from bacterial infections and cholelithiasis, however, immune-mediated cholangitis in primary biliary cholangitis (PBC) and primary sclerosing...

Descripción completa

Detalles Bibliográficos
Autores principales: González, Marisol I., Vannan, Danielle T., Eksteen, Bertus, Flores-Sotelo, Irán, Reyes, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834285/
https://www.ncbi.nlm.nih.gov/pubmed/35159185
http://dx.doi.org/10.3390/cells11030375
_version_ 1784649149362208768
author González, Marisol I.
Vannan, Danielle T.
Eksteen, Bertus
Flores-Sotelo, Irán
Reyes, José Luis
author_facet González, Marisol I.
Vannan, Danielle T.
Eksteen, Bertus
Flores-Sotelo, Irán
Reyes, José Luis
author_sort González, Marisol I.
collection PubMed
description Cholestasis, which is impaired bile flow from the liver into the intestine, can be caused by cholangitis and/or bile duct obstruction. Cholangitis can arise from bacterial infections and cholelithiasis, however, immune-mediated cholangitis in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) is characterized by a strong immune response targeting the biliary epithelial cells (BECs). Persistent biliary inflammation further represents a risk for biliary neoplasia, cholangiocarcinoma (CCA) by driving chronic cellular stress in the BECs. Currently, immune-mediated cholangitis is considered a Th1-Th17-dominant disease, however, the presence of Th2-related mast cells (MCs) in tissue samples from PBC, PSC and CCA patients has been described, showing that these MCs are active players in these diseases. Here, we reviewed and discussed experimental and clinical data supporting a pro-fibrotic role for MCs in immune-mediated cholangitis as well as their participation in supporting tumor growth acting as angiogenesis promoters. Thus, although MCs have classically been identified as downstream effectors of Th2 responses in allergies and parasitic infections, evidence suggests that these MCs are relevant players in biliary inflammation and neoplasia. The availability of strategies to prevent MCs’ activation represents a therapeutic opportunity in biliary diseases.
format Online
Article
Text
id pubmed-8834285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88342852022-02-12 Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma González, Marisol I. Vannan, Danielle T. Eksteen, Bertus Flores-Sotelo, Irán Reyes, José Luis Cells Review Cholestasis, which is impaired bile flow from the liver into the intestine, can be caused by cholangitis and/or bile duct obstruction. Cholangitis can arise from bacterial infections and cholelithiasis, however, immune-mediated cholangitis in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) is characterized by a strong immune response targeting the biliary epithelial cells (BECs). Persistent biliary inflammation further represents a risk for biliary neoplasia, cholangiocarcinoma (CCA) by driving chronic cellular stress in the BECs. Currently, immune-mediated cholangitis is considered a Th1-Th17-dominant disease, however, the presence of Th2-related mast cells (MCs) in tissue samples from PBC, PSC and CCA patients has been described, showing that these MCs are active players in these diseases. Here, we reviewed and discussed experimental and clinical data supporting a pro-fibrotic role for MCs in immune-mediated cholangitis as well as their participation in supporting tumor growth acting as angiogenesis promoters. Thus, although MCs have classically been identified as downstream effectors of Th2 responses in allergies and parasitic infections, evidence suggests that these MCs are relevant players in biliary inflammation and neoplasia. The availability of strategies to prevent MCs’ activation represents a therapeutic opportunity in biliary diseases. MDPI 2022-01-22 /pmc/articles/PMC8834285/ /pubmed/35159185 http://dx.doi.org/10.3390/cells11030375 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
González, Marisol I.
Vannan, Danielle T.
Eksteen, Bertus
Flores-Sotelo, Irán
Reyes, José Luis
Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title_full Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title_fullStr Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title_full_unstemmed Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title_short Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
title_sort mast cells in immune-mediated cholangitis and cholangiocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834285/
https://www.ncbi.nlm.nih.gov/pubmed/35159185
http://dx.doi.org/10.3390/cells11030375
work_keys_str_mv AT gonzalezmarisoli mastcellsinimmunemediatedcholangitisandcholangiocarcinoma
AT vannandaniellet mastcellsinimmunemediatedcholangitisandcholangiocarcinoma
AT eksteenbertus mastcellsinimmunemediatedcholangitisandcholangiocarcinoma
AT floressoteloiran mastcellsinimmunemediatedcholangitisandcholangiocarcinoma
AT reyesjoseluis mastcellsinimmunemediatedcholangitisandcholangiocarcinoma